PBA
GPCR icon

Paradigm Biocapital Advisors’s Structure Therapeutics GPCR Stock Holding History

Paradigm Biocapital Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-545,287
Closed -$26.3M – 33
2026
Q1 		$26.3M Buy
+545,287
New +$37.3M 0.54% 30
2025
Q4 		– Sell
-372,869
Closed -$10.4M – 37
2025
Q3 		$10.4M Buy
+372,869
New +$7.43M 0.3% 35

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Paradigm Biocapital Advisors's GPCR Position: Q2 2026 in Review

Paradigm Biocapital Advisors sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 545,287 shares — an estimated $26.3M sold.

Paradigm Biocapital Advisors first reported a position in GPCR in Q3 2025 and held it in 2 quarters. The position peaked at $26.3M in Q1 2026. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Paradigm Biocapital Advisors reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 545,287 Structure Therapeutics shares in Q2 2026, an estimated $26.3M.
  • Paradigm Biocapital Advisors first reported a position in Structure Therapeutics in Q3 2025 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's Structure Therapeutics position peaked at $26.3M in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.